Silence Therapeutics PLC · NASDAQ:SLN

Silence Therapeutics — Investor Presentation (January 2023)

36 slides from Silence Therapeutics's investor presentation, January 2023

  1. Slide 1: Silence Therapeutics

    Silence Therapeutics January 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation

  3. Slide 3: Silencing diseases through precision engineered medicines created with proprietary siRNA technology

    Silencing diseases through precision engineered medicines created with proprietary siRNA technology

  4. Slide 4: Evolution of Silence

    Evolution of Silence • Focus shifted to GalNAc siRNA siRNA work begins in AIM listing, company named expertise our Berlin research labs Silence Therapeutics plc • Robust IP protection activity (10 technology patent families) • Multiple big pharma partnerships • Nasdaq listing siRNA technology 1998 2

  5. Slide 5: Global Footprint

    Global Footprint LONDON BERLIN COMPANY HQ R&D OPERATIONS NEW JERSEY US OFFICE 125 EMPLOYEES WORLDWIDE 5

  6. Slide 6: Precision Engineered Medicines to Silence Disease

    Precision Engineered Medicines to Silence Disease The Silence siRNA Platform • Precision engineered medicines: each siRNA is uniquely designed to only bind to the target mRNA, which can reduce potential for side effects • Broad Utility: targeting both rare and common genetic diseases • Durability, y

  7. Slide 7: The Difference Between Gene Silencing, Gene Therapy and Gene Editing

    The Difference Between Gene Silencing, Gene Therapy and Gene Editing Gene Silencing Gene Therapy Gene Editing Prevents expression of a disease-related Compensates for a disease-related gene by Corrects a disease-related gene by gene by targeting the mRNA it produces delivering a functional copy of i

  8. Slide 8: Our Toolbox Considers all Elements of siRNA and Ligand Design

    Our Toolbox Considers all Elements of siRNA and Ligand Design siRNA molecule Linker GalNAc Ligand (delivery tool) • siRNA matched to target gene • Silence has developed • GalNAc ligand delivers proprietary linkers, enabling molecule to specific liver • Silence has developed chemical the attachment o

  9. Slide 9: Our Strategy to Maximize mRNAi GOLD

    Our Strategy to Maximize mRNAi GOLD™ Hybrid Model Wholly owned programs that focus and leverage the company’s expertise in specific areas with the most opportunity PIPELINE Partnered programs provide collaboration for a broader reach and potential source for non- dilutive capital Strategy balances r

  10. Slide 10: Early-stage GalNAc-conjugated RNAi Programs Have a Much Greater Likelihood of Approval vs. Industry Average

    Early-stage GalNAc-conjugated RNAi Programs Have a Much Greater Likelihood of Approval vs. Industry Average Likelihood of Approval from Current Phase: GalNAc RNAi vs. others 100% 80% 67% GalNAc-conjugated 56% RNAi 60% 51% 53% Pharma industry 40% average (excluding GalNAc- 17% conjugated RNAi) 20% 9%

  11. Slide 11: Partnership Programs Further Expand Pipeline and Provide ~$7.5 Billion in Potential Milestones Plus Royalties

    Partnership Programs Further Expand Pipeline and Provide ~$7.5 Billion in Potential Milestones Plus Royalties Signed deal to discover, develop and commercialize siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases in March 2020 • Upfront cash payment of $60 million and an

  12. Slide 12: Pipeline Balances Proprietary & Partnered Programs

    Pipeline Balances Proprietary & Partnered Programs Indication Target Discovery Preclinical Phase I Phase II Phase III Proprietary/Partnered Cardiovascular SLN360 disease due to high Lp(a) Lp(a) Beta Thalassemia SLN124 TMPRSS6 Polycythemia Vera (PV) Multiple Programs Undisclosed Undisclosed SLN-HAN-1

  13. Slide 13: Clinical Programs

    Clinical Programs 13

  14. Slide 14: Positive Clinical Data Shown in Two mRNAi GOLD Platform Programs

    Positive Clinical Data Shown in Two mRNAi GOLD™ Platform Programs Targeting Common and Rare Diseases Target Ph 1 Study Efficacy Durability Safety / Tolerability 32 healthy Lp(a) reductions Effects persisting Well tolerated with no volunteers SLN360 LPA with high observed up to 98% over a five-month

  15. Slide 15: SLN360

    SLN360 Cardiovascular Disease 15

  16. Slide 16: SLN360 Targets Lp(a): an Independent Risk Factor for Cardiovascular Disease

    SLN360 Targets Lp(a): an Independent Risk Factor for Cardiovascular Disease Large population worldwide with up to 10% with >90 mg/dL1 (2-3x increased heart attack risk)2 Lp(a) levels are genetically determined Recognized as a major untreated risk factor in cardiovascular disease Lp(a) levels are not

  17. Slide 17: Cardiovascular Event Risk Significantly Increases with High Lp(a)

    Cardiovascular Event Risk Significantly Increases with High Lp(a) Substantial Risk of CV Event at Lp(a) ~90 mg/dL 780 Million Worldwide with >90 mg/dL Lp(a) Event Increased Risk Lp(a) level: >50 mg/dL >90 mg/dL Heart Attack1 2 - 3x Prevalence6 ~20% ~10% Aortic Stenosis2 2 - 3x USA 66m 33m EU 103m 51

  18. Slide 18: SLN360 Has Substantial Market Potential

    SLN360 Has Substantial Market Potential High Cholesterol vs High Lp(a) in Cardiovascular Disease High Cholesterol is a Modifiable Risk Factor Lifestyle changes can have a positive impact High Lp(a) is a Genetic Risk Factor Lifestyle changes have no effect on Lp(a) levels Similar Medically Treated Po

  19. Slide 19: Growing Awareness of Lp(a) as a Key CV Risk Factor

    Growing Awareness of Lp(a) as a Key CV Risk Factor 2022 European 2021 Canadian 2018 AHA/ACC Atherosclerosis Society Cardiovascular Society Consensus Statement (CCS) Relative indications for its measurement are a family Lp(a) should be measured Lp(a) measurement for history of premature ASCVD at leas

  20. Slide 20: SLN360 Phase 1 Program Overview

    SLN360 Phase 1 Program Overview Global randomized, double-blind, placebo controlled Design single dose and multiple dose study Investigate the safety, tolerability, PK and PD response Aim of SLN360 s.c. dosing in subjects with high Lp(a) ≥ 150 nmol/L • Enrolled 32 healthy adults with high Lp(a) Sing

  21. Slide 21: SLN360 Lowered Lp(a) Up to 98% After a Single Dose in Phase 1 Study

    SLN360 Lowered Lp(a) Up to 98% After a Single Dose in Phase 1 Study in Healthy Adults with High Lp(a) 0% -10% Lipoprotein(a) Change (%) -20% -30% -40% -50% 70% 96% reduction -60% reduction -70% 98% -80% reduction -90% 81% reduction -100% Baseline Day 7 Day 14 Day 30 Day 45 Day 60 Day 90 Day 150 Plac

  22. Slide 22: Results Presented in a Late Breaker at the ACC Annual Meeting and Published in JAMA

    Results Simultaneously Presented in a Late Breaker at the ACC Annual Meeting and Published in JAMA in April 2022 We thought it would work, but we were surprised by the magnitude and the duration of the effect. Lipoprotein(a) is the last frontier in lipids... Steven E. Nissen, M.D., Chief Academic Of

  23. Slide 23: SLN360 Phase 2 Study Overview

    SLN360 Phase 2 Study Overview Design Multi-center, randomized, double-blind, placebo-controlled, phase 2 study Investigate the efficacy, safety and tolerability of SLN360 s.c. dosing in subjects with Aim high Lp(a) ≥ 125 nmol/L at high risk of ASCVD events Enrollment ~160 participants Dosing 2 SLN36

  24. Slide 24: Anticipated Milestones for SLN360 Program

    Anticipated Milestones for SLN360 Program Phase 1 multiple dose data in patients with high Lp(a) and stable ASCVD 4Q 2023 Complete Phase 2 high risk ASCVD study enrollment 4Q 2023 24

  25. Slide 25: SLN124

    SLN124 Hematological Disorders 25

  26. Slide 26: SLN124 Has Potential for Broad Mechanistic Mode of Action Approach

    26 SLN124 Has Potential for Broad Mechanistic Mode of Action Approach SLN124 targets Positive preclinical data Proof of mechanism TMPRSS6 and modulates showing therapeutic demonstrated in hepcidin – the body’s potential in several healthy volunteer master iron regulator hematological disorders study

  27. Slide 27: SLN124 Clinical Programs

    SLN124 Clinical Programs Iron Loading Anemias (Beta Thalassemia) • Globin gene mutations interfere with red blood cell production and cause anemia ~5,000 • The majority are dependent on regular blood transfusions (TDT), Prevalence while others are transfused less frequently (NTDT) 1/100,0001,2,3 ~10

  28. Slide 28: SLN124 Proof of Mechanism Established in Healthy Volunteer Study

    SLN124 Proof of Mechanism Established in Healthy Volunteer Study SLN124 increased average hepcidin up to ~4-fold and EFFICACY reduced serum iron ~50% after a single dose DURABILITY Activity persisted for at least 2 months (study period) SAFETY Well tolerated with no serious or severe treatment emerg

  29. Slide 29: SLN124 Increased Average Hepcidin up to ~4-Fold After a Single Dose

    SLN124 Increased Average Hepcidin up to ~4-Fold After a Single Dose with Activity Sustained for ≥ 2 Months 12 3.9x 10 Hepcidin (nmol), mean and fold increase 3.3x 8 2.3x 6 2.4x 2.1x 2.2x 4 2 0 Placebo SLN124 1.0 mg/kg SLN124 3.0 mg/kg SLN124 4.5 mg/kg n=6 healthy volunteers in each treatment group B

  30. Slide 30: SLN124 Reduced Serum Iron by ~50% After a Single Dose

    SLN124 Reduced Serum Iron by ~50% After a Single Dose with Activity Sustained for ≥ 2 Months 25 20 Iron (µmol/L), mean and % change 15 -22% -24% -42% -16% 10 -47% -48% 5 0 Placebo SLN124 1.0 mg/kg SLN124 3.0 mg/kg SLN124 4.5 mg/kg n=6 healthy volunteers in each treatment group Baseline Day 29 Day 57

  31. Slide 31: SLN124 Phase 1 Program in Adult Thalassemia

    SLN124 Phase 1 Program in Adult Thalassemia Global, randomized, single-blind, placebo-controlled Design single dose and multiple dose study Investigate the safety, tolerability, PK and PD response Aim of SLN124 s.c. dosing in adults with NTD thalassemia Enrollment ~ 24 adults with NTD thalassemia Do

  32. Slide 32: Preliminary Single Dose Results from SLN124 Phase 1 Study in Thalassemia Patients

    Preliminary Single Dose Results from SLN124 Phase 1 Study in Thalassemia Patients • No serious adverse events, no severe TEAEs that were SLN124 related • No TEAEs leading to withdrawal • No dose limiting toxicities or drug related liver injury were observed • Effects on hepcidin, serum iron, transfe

  33. Slide 33: SLN124 Phase 1/2 Study in Polycythemia Vera (PV)

    SLN124 Phase 1/2 Study in Polycythemia Vera (PV) Phase 1 is an open-label, dose-finding study Design Phase 2 is a randomized, double-blind, placebo-controlled study Aim Assess the safety, tolerability, efficacy, PK, and PD response of SLN124 s.c. dosing in patients with PV Enrollment Up to 65 partic

  34. Slide 34: Financial Highlights

    Financial Highlights SLN: Nasdaq Stock Price (1/4/23) $15.41 per ADS Common Shares Outstanding (9/30/22) ~35,893,337 ADS Market Capitalization (1/4/23) ~$553m Cash (9/30/22) ~$113m Debt $0 Note: ADS each represent 3 ordinary shares nominal value 34

  35. Slide 35: Key Investment Highlights

    Key Investment Highlights • Wholly owned SLN360 program targeting large cardiovascular indication with high unmet need ‒ Phase 2 ASCVD study now underway • Second wholly owned SLN124 program has shown potential in multiple hematological diseases ‒ PV study open for enrollment • Partnered pipeline re

  36. Slide 36: Silencing diseases through precision engineered medicines created with proprietary siRNA technology

    Silencing diseases through precision engineered medicines created with proprietary siRNA technology

Silence Therapeutics — Investor Presentation (January 2023) on 6ix